Feng Shi

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Yihebali Chi, Xiangqian Zheng, Yuan Zhang et al. · Clinical Cancer Research · 2023 · 37 citations · Full text

Medicine, Oncology, Pharmacology +11

Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Yansong Lin, Shukui Qin, Hui Yang et al. · Clinical Cancer Research · 2023 · 22 citations

Medicine, Oncology, Pharmacology +9

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey R. Ager, Matthew J. Reilley, Courtney Nicholas et al. · Journal for ImmunoTherapy of Cancer · 2016 · 17 citations · Full text

Medicine, Immunology, Oncology +17

Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data

Lujun Shen, Yiquan Jiang, Linbin Lu et al. · The Innovation Medicine · 2025 · 14 citations · Full text

Medicine, Oncology, Machine Learning +16

265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

Y. Chi, Ming Gao, Y. Zhang et al. · Annals of Oncology · 2020 · 10 citations

Medicine, Endocrinology, Oncology +9